The safe and effective use of methylphenidate in the psychiatric treatment of an adolescent with Epidermolysis Bullosa

Year 2013, Volume: 38 Issue: 3, 487 - 491, 01.09.2013

Özalp Ekinci Tanju Çelik Asena Çiğdem Doğramacı Fevziye Toros

Abstract

Epidermolysis Bullosa is a group of inherited dermatological disorder with severe clinical symptoms. Children and adolescents with epidermolysis bullosa have been reported to experience psychosocial problems in addition to the symptoms associated with epidermolysis bullosa. Although children and adolescents with epidermolysis bullosa commonly have psychiatric symptoms, limited research has been conducted on the psychiatric treatment options. In this case report, psychiatric treatment and the safe and effective use of methylphenidate in the treatment of attention deficit hyperactivity disorder in an adolescent with epidermolysis bullosa will be discussed.

Keywords

Epidermolysis bullosa, methylphenidate, adolescent, attention deficit hyperactivity disorder

Epidermolizis Büllosa tanılı bir ergenin psikiyatrik tedavisinde Metilfenidat"ın güvenli ve etkin kullanımı

Abstract

Epidermolizis Büllosa şiddetli klinik belirtilerle giden genetik kökenli bir deri hastalığı grubudur. Epidermolizis büllosa tanılı çocuk ve ergenlerin hastalık ile ilişkili belirtilerin yanı sıra psikososyal sorunlar da yaşadıkları bildirilmiştir. Epidermolizis büllosa tanılı çocuk ve ergenlerde psikiyatrik belirtilere sık olarak rastlanmasına karşın psikiyatrik tedavi seçenekleri üzerine sınırlı sayıda araştırma yapılmıştır. Bu olgu sunumunda epidermolizis büllosa tanılı bir ergende psikiyatrik tedavi ve dikkat eksikliği hiperaktivite bozukluğu tedavisinde metilfenidat (MPH)"ın güvenli ve etkin kullanımı tartışılmıştır.

Keywords

Epidermolizis Büllosa, metilfenidat, ergen, dikkat eksikliği hiperaktivite bozukluğu

References

• Sawamura D, Nakano H, Matsuzaki Y. Overview of epidermolysis bullosa. J Dermatol. 2010; 37:214-9.
• Tabolli S, Sampogna F, Di Pietro C, Paradisi A, Uras C, Zotti P, et al. Quality of life in patients with epidermolysis bullosa. Br J Dermatol. 2009; 161:869
• Margari F, Lecce PA, Santamato W, Ventura P, Sportelli N, Annicchiarico G, , et al. Psychiatric symptoms and quality of life in patients affected by epidermolysis bullosa. J Clin Psychol Med Settings. 2010; 17:333-9.
• Van Scheppingen C, Lettinga AT, Duipmans JC, Maathuis CG, Jonkman MF. Main problems experienced by children with epidermolysis bullosa: a qualitative study with semi-structured interviews. Acta Derm Venereol. 2008; 88:143-50.
• Fine JD, Johnson LB, Weiner M, Suchindran C. Assessment of mobility, activities and pain in different subtypes of epidermolysis bullosa. Clin Exp Dermatol. 2003; 29:122–7.
• Horn HM, Tidman J. Quality of life in epidermolysis bullosa. Clin Exp Dermatol. 2002; 27:707–710.
• Andreoli E, Mozzetta A, Angelo C, Paradisi M, Foglio Bonda PG. Epidermolysis bullosa, psychological and psychosocial aspects. Dermatology and Psychosomatics. 2002; 3:77–81.
• Hall S. Life, epidermolysis bullosa and chasing tornadoes. J Wound Care. 2004; 13:405–6.
• Dietz, MJ. A day in the life of a patient with DDEB. J Am Acad Dermatol. 2004; 51:58-9.
• Williams EF, Gannon K, Soon K. The experiences of young people with Epidermolysis Bullosa Simplex: a qualitative study. J Health Psychol. 2011; 16:701-10.
• Findling RL. Evolution of the treatment of attentiondeficit/hyperactivity disorder in children: a review. Clin Ther. 2008; 30:942-57.
• Georgiopoulos AM, Hua LL. The diagnosis and treatment of attention deficit-hyperactivity disorder in children and adolescents with cystic fibrosis: a retrospective study. Psychosomatics. 2011; 52:160-6.
• Graham, Johnny; Coghill, David Adverse Effects of Pharmacotherapies for Attention-Deficit Hyperactivity Disorder: Epidemiology, Prevention and Management. CNS Drugs. 2008; 22:213-37.
• Confino-Cohen R, Goldberg A. Successful desensitization of methylphenidate-induced rash. J Child Adolesc Psychopharmacol. 2005; 15:703-5.
• Coskun M, Tutkunkardas MD, Zoroglu S. OROS methylphenidate-induced skin eruptions J Child Adolesc Psychopharmacol. 2009; 19:593-4.
• Vashi NA, Souza A, Cohen N, Franklin B, Cohen DE. Allergic contact dermatitis caused by methylphenidate. Contact Dermatitis. 2011; 65:183-5.
• Heinzerling LM, Pichler W, Anliker MD. Acute generalized exanthematous pustulosis induced by methylphenidate: a new adverse effect. Arch Dermatol. 2011; 147:872-3.
• Sharp SC, Hellings JA. Efficacy and safety of selective serotonin reuptake inhibitors in the treatment of depression in children and adolescents: practitioner review. Clin Drug Investig. 2006; 26:247
• MacQueen G, Born L, Steiner M. The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. CNS Drug Rev. 2001; 7:1Bozdogan N, Yildirim SV. Intranasal clonidine as a premedicant: three cases with unique indications. Paediatr Anaesth. 2008; 18:800.
• Sidwell RU, Yates R, Atherton D. Dilated cardiomyopathy in dystrophic epidermolysis bullosa. Arch Dis Child. 2000;83:59-63.
• Lara-Corrales I, Pope E. Dilated cardiomyopathy in epidermolysis bullosa. Dermatol Clin. 2010; 28:347
• Ergül Y, Nişli K, Avcı B, Omeroğlu RE. Dilated cardiomyopathy associated with dystrophic epidermolysis bullosa: role of micronutrient deficiency? Turk Kardiyol Dern Ars. 2011; 39:328-31.
• Winterstein AG, Gerhard T, Shuster J, Saidi A. Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. Pediatrics. 2009; 124:75-80.
• Dopheide JA, Pliszka SR. Attention-deficithyperactivity disorder: an update. Pharmacotherapy. 2009; 29:656-79.
• Green T, Weinberger R, Diamond A, et al. The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome. J Child Adolesc Psychopharmacol. 2011; 21:589-95.
• Yazışma Adresi / Address for Correspondence: Dr. Özalp Ekinci Mersin Üniversitesi Tıp Fakültesi Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları Anabilim Dalı 33079 MERSİN e-mail: ö[e-mail] geliş tarihi/received :24.09.2012 kabul tarihi/accepted:07.12.2012